Keyword: Ocrevus

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Sanofi has struggled to rev up multiple sclerosis therapy Lemtrada, but some new long-term data might help it win over doctors and patients.

Roche's new five-year Ocrevus data could ratchet up the enthusiasm for the drug—and sway more payers to cover it.

Pharma may have Trump administration allies, but across the pond, Health Minister Matt Hancock has attacked, aiming his toughest remarks at Vertex.

Roche says England's health service—not Ocrevus' price—is to blame as cost watchdogs again reject the med for primary progressive MS.

Over the last few years, the multiple sclerosis field has been a hotbed for formulary management. But that’s changed a bit in 2018.

With biosimilar versions of its top drugs on the horizon, Roche's Genentech unit is parting ways with 223 staffers in California.

Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.

Biogen grew sales 9% in the second quarter, beating Street expectations, but analysts on the company's conference call were focused elsewhere.

England’s cost watchdogs aren’t going to pay for Roche's Ocrevus, the only approved PPMS therapy—that is, until it gets cheaper.